4篇
您的检索式：作者名="Monica Robotin"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatitis B prevention and control:Lessons from the East and the West显示文摘Despite being ten times more common than HIV infection,viral hepatitis has so far not commanded the same public health response worldwide,so a global viral hepatitis treatment program is still a long way from becoming a reality.However,much progress has occurred over the last few decades,with the screening of blood products,sound infection control practices and the introduction of disposable needles and syringes leading to signif icant reductions in nosocomial hepatitis B transmission in the developed world and increasingly in other countries.The introduction of hepatitis B vaccination in the 1980s and its integration into the Expanded Immunization Program have led to substantial reductions in chronic hepatitis B infection rates in children and to millions of lives saved.The availability of effective antiviral treatment has revolutionized treatment prospects,although access to treatment remains a significant challenge for most developed countries and re mains out of reach for developing nations.Some of these breakthroughs have occurred in Asian countries,others in the West,but their unifying features are innov ative research,timely clinical translation and a com mitment to apply their findings to improve the healt h of populations,not just individuals.This paper reviews some of the challenges and opportunities for hepat itis B control at the end of the f irst decade of the third millennium and argues for closer East-West collaborations,to bring in fresh perspectives,avoid dupl ications of effort and in order to help answer many of the remaining challenges in making hepatitis B history. | Monica C Robotin | 2011 | World Journal of Hepatology2011，3，2： | 2 |
| 2 | Getting it right: the impact of a continuing medical education program on hepatitis B knowledge of Australian primary care providers显示文摘 | Monica Robotin George Patton | 2013 | International Journal of General Medicine (default)2013，，： | 1 |
| 3 | Getting it right: the impact of a continuing medical education program on hepatitis B knowledge of Australian primary care providers显示文摘 | Monica Robotin George Patton | 2013 | International Journal of General Medicine . 2013 (defa)2013，，： | 1 |
| 4 | Cost of treating chronic hepatitis B:Comparison of current treatment guidelines显示文摘AIM:To compare program costs of chronic hepatitis B(CHB) screening and treatment using Australian and other published CHB treatment guidelines.METHODS:Economic modeling demonstrated that in Australia a strategy of hepatocellular cancer(HCC) prevention in patients with CHB is more cost-effective than current standard care,or HCC screening.Based upon this model,we developed the B positive program to optimize CHB management of Australians born in countries of high CHB prevalence.We estimated CHB program costs using the B positive program algorithm and compared them to estimated costs of using the CHB treatment guidelines published by the AsianPacific,American and European Associations for the Study of Liver Disease(APASL,AASLD,EASL) and those suggested by an independent United States hepatology panel.We used a Markov model that factored in the costs of CHB screening and treatment,individualized by viral load and alanine aminotransferase levels,and calculated the relative costs of program components.Costs were discounted by 5% and calculated in Australian dollars(AUD).RESULTS:Using the B positive algorithm,total program costs amount to 13 979 224 AUD,or 9634 AUD per patient.The least costly strategy is based upon using the AASLD guidelines,which would cost 34% less than our B positive algorithm.Using the EASL and the United States Expert Group guidelines would increase program costs by 46%.The largest expenditure relates to the cost of drug treatment(66.9% of total program costs).The contribution of CHB surveillance(20.2%) and HCC screening and surveillance(6.6%) is small-and together they represent only approximately a quarter of the total program costs.CONCLUSION:The significant cost variations in CHB screening and treatment using different guidelines are relevant for clinicians and policy makers involved in designing population-based disease control programs. | Monica Robotin Yumi Patton Melanie Kansil Andrew Penman Jacob George | 2012 | World Journal of Gastroenterology2012，18，42： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员